乳腺癌患者的高钙血症：一项生存研究。
Hypercalcemia in patients with breast cancer: a survival study.
作者信息
de Wit S, Cleton F J
机构信息
Department of Clinical Oncology, University Hospital Leiden, The Netherlands.
出版信息
J Cancer Res Clin Oncol. 1994;120(10):610-4. doi: 10.1007/BF01212816.
Abstract
In a retrospective study survival after hypercalcemia in breast cancer patients has been investigated. A group of 72 patients were treated with bisphosphonate APD [3-(amino-1,1-hydroxypropylidene)bisphosphonate] and third-generation amino-containing bisphosphonates between January 1980 and October 1992. A median survival of 4.5 months was found. In a multivariate analysis, four independent prognostic factors for survival have been found: the interval between first relapse and hypercalcemia, sites of metastases at the moment of hypercalcemia, primary treatment, and the level of serum alkaline phosphatase. Patients with a "flare" reaction on tamoxifen treatment and patients with a normal serum alkaline phosphatase level and bone metastases only had a prolonged survival. Hypercalcemia associated with visceral metastases carried a very poor prognosis. The level of serum calcium in this series of patients was no prognostic indicator for survival.
摘要
在一项回顾性研究中，对乳腺癌患者高钙血症后的生存情况进行了调查。1980年1月至1992年10月期间，一组72例患者接受了双膦酸盐APD[3-(氨基-1,1-羟基亚丙基)双膦酸盐]和第三代含氨基双膦酸盐治疗。发现中位生存期为4.5个月。在多变量分析中，发现了四个影响生存的独立预后因素：首次复发与高钙血症之间的间隔、高钙血症时的转移部位、初始治疗以及血清碱性磷酸酶水平。他莫昔芬治疗出现“flare”反应的患者以及血清碱性磷酸酶水平正常且仅有骨转移的患者生存期延长。伴有内脏转移的高钙血症预后极差。该系列患者的血清钙水平并非生存的预后指标。
相似文献
1
Hypercalcemia in patients with breast cancer: a survival study.乳腺癌患者的高钙血症：一项生存研究。
J Cancer Res Clin Oncol. 1994;120(10):610-4. doi: 10.1007/BF01212816.
2
Bisphosphonates and other bone agents for breast cancer.用于乳腺癌的双膦酸盐及其他骨治疗药物。
Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD003474. doi: 10.1002/14651858.CD003474.pub4.
3
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
4
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
5
Bisphosphonates and other bone agents for breast cancer.用于乳腺癌的双膦酸盐及其他骨药物。
Cochrane Database Syst Rev. 2012 Feb 15(2):CD003474. doi: 10.1002/14651858.CD003474.pub3.
6
Prognosis and Phenotypes of Advanced Head and Neck Carcinoma Associated With Hypercalcemia.与高钙血症相关的晚期头颈癌的预后和表型
Head Neck. 2025 Aug;47(8):2174-2182. doi: 10.1002/hed.28126. Epub 2025 Mar 11.
7
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
8
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2002(1):CD003474. doi: 10.1002/14651858.CD003474.
9
Bisphosphonates in multiple myeloma: an updated network meta-analysis.双膦酸盐类药物在多发性骨髓瘤中的应用：一项更新的网状Meta分析
Cochrane Database Syst Rev. 2017 Dec 18;12(12):CD003188. doi: 10.1002/14651858.CD003188.pub4.
10
A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression.一项关于恶性脊柱转移瘤的证据的系统回顾：自然病史和识别高风险椎体骨折和脊髓压迫患者的技术。
Health Technol Assess. 2013 Sep;17(42):1-274. doi: 10.3310/hta17420.
引用本文的文献
1
Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift.西那卡塞治疗恶性肿瘤相关性高钙血症：一种范式转变。
Endocr Connect. 2021 Jan;10(1):R13-R24. doi: 10.1530/EC-20-0487.
2
Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?妇科肿瘤患者高钙血症的住院治疗预示着预后不良：是否是启动临终关怀的触发因素？
Gynecol Oncol Rep. 2019 Jan 26;28:1-5. doi: 10.1016/j.gore.2019.01.005. eCollection 2019 May.
3
Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes.晚期实体瘤中与恶性肿瘤相关的高钙血症：生存结果
J Glob Oncol. 2017 Dec;3(6):728-733. doi: 10.1200/JGO.2016.006890. Epub 2017 Mar 15.
4
Association of calcium sensing receptor polymorphisms at rs1801725 with circulating calcium in breast cancer patients.乳腺癌患者中rs1801725位点钙敏感受体基因多态性与循环钙水平的关联
BMC Cancer. 2017 Aug 2;17(1):511. doi: 10.1186/s12885-017-3502-3.
5
Hypercalcaemia and hypocalcaemia: finding the balance.高钙血症与低钙血症：寻求平衡
Support Care Cancer. 2017 May;25(5):1639-1649. doi: 10.1007/s00520-016-3543-1. Epub 2017 Jan 12.
6
Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study.未知原发部位恶性肿瘤预后因素评估及化疗的作用：一项10年队列研究
BMC Res Notes. 2012 Jan 26;5:70. doi: 10.1186/1756-0500-5-70.
7
Flare hypercalcemia after letrozole in a patient with liver metastasis from breast cancer: a case report.来曲唑治疗后发生 flare 高钙血症的乳腺癌肝转移患者 1 例报告
J Med Case Rep. 2011 Oct 4;5:495. doi: 10.1186/1752-1947-5-495.
8
Hypercalcemia-leukocytosis syndrome in a patient with cavitating squamous cell carcinoma of the lung.
Cases J. 2009 Jan 31;2(1):108. doi: 10.1186/1757-1626-2-108.
9
Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis.静脉注射双膦酸盐治疗癌症相关高钙血症：生存及预后因素分析
Support Care Cancer. 2008 Apr;16(4):387-92. doi: 10.1007/s00520-007-0322-z. Epub 2007 Aug 21.
10
Emergencies of calcium homeostasis.钙稳态的紧急情况。
Rev Endocr Metab Disord. 2003 May;4(2):167-75. doi: 10.1023/a:1022994104070.
本文引用的文献
1
Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
Breast Cancer Res Treat. 1993;25(3):277-81. doi: 10.1007/BF00689842.
2
Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges for future research.肿瘤诱导的高钙血症和肿瘤诱导的骨溶解的医学治疗：未来研究面临的挑战。
Support Care Cancer. 1993 Jan;1(1):26-33. doi: 10.1007/BF00326636.
3
Palliative pamidronate treatment in patients with bone metastases from breast cancer.乳腺癌骨转移患者的姑息性帕米膦酸治疗。
J Clin Oncol. 1993 Mar;11(3):491-8. doi: 10.1200/JCO.1993.11.3.491.
4
Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia.
Lancet. 1983 Jul 30;2(8344):239-43. doi: 10.1016/s0140-6736(83)90231-3.
5
The clinical course of bone metastases from breast cancer.乳腺癌骨转移的临床病程。
Br J Cancer. 1987 Jan;55(1):61-6. doi: 10.1038/bjc.1987.13.
6
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.3-（氨基-1,1-羟基亚丙基）双膦酸盐（APD）治疗乳腺癌高钙血症。
Br J Cancer. 1987 Oct;56(4):465-9. doi: 10.1038/bjc.1987.225.
7
Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.
Am J Med. 1987 Jun;82(6):1133-42. doi: 10.1016/0002-9343(87)90215-4.
8
Bone metastases and breast cancer.骨转移与乳腺癌。
Cancer Treat Rev. 1985 Dec;12(4):251-70. doi: 10.1016/0305-7372(85)90008-8.
9
Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.氨基羟丙基二膦酸盐、光辉霉素及皮质类固醇/降钙素治疗癌性高钙血症的比较
Lancet. 1985 Oct 26;2(8461):907-10. doi: 10.1016/s0140-6736(85)90848-7.
10
Hypercalcaemia in patients with disseminated breast cancer.转移性乳腺癌患者的高钙血症
Acta Oncol. 1990;29(5):577-80. doi: 10.3109/02841869009090054.
Zotero 插件